A Remarkable Colorectal Cancer Immunotherapy Meeting

As my most recent Currently Incurable Scientist column began: On December 2, 2015 a remarkable meeting took place. Jointly organized by Fight Colorectal Cancer (Fight CRC) and the leading immuno-oncology organization the Cancer Research Institute (CRI), an unprecedented meeting gathered many of the world’s leading experts on both CRC and immuno-oncology. Top scientists devoted to CRC research sat around the same table together for the first time to discuss what is needed to advance immunotherapy for CRC.

An Unrealized Love of Writing Expands_Fight CRC Pic cancer-research-institute

This meeting was both unprecedented and I believe absolutely necessary for the CRC patient community – so I wanted to present here in my personal blog a few Director’s Cut bonus features, trying to explain the viewpoint of the meeting from both a scientist’s as well as a currently incurable patient’s eyes.

The Directors Cut

Who was there? Leading experts in both CRC & immuno-oncology, from both public and private institutions: Dr. Al Benson (Northwestern U), Dr. Emily Chan (Vanderbilt U), Dr. Dustin  Deming (U of WI) Dr. Luis Diaz (Johns Hopkins), Dr. Wolf Fridman (INSERM), Dr. Franck Housseau (Johns Hopkins), Dr. S. Peter Kang (Merck), Dr. Smitha Krishnamurth (Case Western U), Dr. Dung T Le (Johns Hopkins), Dr. Wells Messersmith (U of CO), Dr. Cynthia L. Sears (Johns Hopkins), Dr. Neil Segal (Memorial Sloan Kettering Cancer Center), Dr. Arvin Yang (Bristol-Myers Squibb), Dr. Rebecca Moss (Bristol-Myers Squibb), Dr. Edward Cha (Genentech), Dr. Tom Dubensky (Aduro Biotech), and Dr. Dirk Brockstedt (Aduro Biotech) as well as representatives from both Fight CRC and the Cancer Research Institute.

2015-12_FCRC-CRI Roundtable CRC-IO Experts

I was thrilled and grateful to be involved with this meeting via both my close partnership with Fight CRC as well as my growing relationship with the Cancer Research Institute – a relationship which now includes my first opportunity to write for an immuno-oncology website as well as becoming the Cancer Research Institute’s “immunoadvocate” for colorectal cancer.  As a strong proponent of immunotherapies, being both their immunoadvocate and a part of this meeting was a scientific dream come true!

Why This Kind of Meeting is Important and Exciting

There are many benefits to bringing together experts for this kind of focused discussion.  Science, especially immuno-oncology, is incredibly complex.  Attacking this kind of scientific problem has the greatest chance of success when the latest information and ideas are discussed in person by experts in a collaborative environment.  They can exchange the latest knowledge from their respective studies in a dynamic conversation format.  They can focus attention on key scientific unknowns still unanswered. They can brainstorm new ideas and approaches.  They can explore new joint strategies. This meeting was intended to foster exactly those goals, to push the science forward.  To push the field closer to a cure.

The Big Goal

Was the meeting intended to announce a major research breakthrough that immediately solves the non-MSI CRC immunotherapy issue? No, it was not.

Instead: This panel of experts came together from academia and industry with this BIG GOAL on their plate: determining the blueprint needed to better understand the science of CRC immunotherapy in order to ultimately maximize its potential to treat ALL forms of CRC

As I wrote about previously, there are already strong preliminary signs that the “microsatellite instable” (MSI-high) subtype of CRC is responding to anti-PD-1 immunotherapy.  Since I wrote that column, the PD-1 inhibitor pembrolizumab (Keytruda™) has been granted a “breakthrough drug designation” by the FDA in order to accelerate its development for MSI-high CRC. Although this is a fantastic development for the MSI-high sub-type of CRC, unfortunately most people diagnosed with CRC are non-MSI.

Non-MSI CRC has proven to be more resistant to treatment by immunotherapies.

The key question is why?

You can’t answer a scientific problem rationally unless you first truly know the question(s) that are needed to be answered in order to move a field forward & achieve the BIG GOAL.  Thus, trying to answer that “why question” was a focus of the experts’ discussion.  The question can (and needs to) be asked from a number of different ways:

  • What are the key reasons why MSI-high CRC responds to anti-PD-1 therapies?
  • What are the key reasons why non-MSI CRC is resistant?
  • Are there outlier patients whose study can give clues on new successful therapeutic strategies?
  • Are there therapies that could be used to make non-MSI CRC “look like” MSI-high CRC and become responsive to anti-PD-1 therapies?
  • Are there non-PD-1 based immunotherapy strategies which may be more appropriate for non-MSI CRC?

The Non-MSI CRC Patient Population is Crying for Help

There is a sense of urgency in the Stage IV CRC patient population.  I share it – we all do – for very obvious reasons.  In my observation, this sense of urgency is even higher in the non-MSI patient population.   This sense of so far unanswered non-MSI urgency leads to frustration.  Due to the high stakes and pressure involved, this frustration at times can boil over into anger.

After seeing the preliminary signs of success in MSI-high clinical trials and the ensuing explosion in MSI-high follow-up clinical trials, I can sense a very real feeling of worry (panic for some?) within the non-MSI patient population that they are not a focus of immunotherapy research now that MSI-high CRC is achieving so much immunotherapy success. I believe this worry is unfounded.  A goal I have for this roundtable is to show to the non-MSI patient population that yes – scientists know how urgently they are in need of new therapies and yes, they are working hard on the non-MSI CRC immunotherapy problem!

As a patient keeping an eye on the game clock, I struggle with the pace of science.  As a scientist, I know that the issues being addressed are very complex (although I firmly believe solvable).  Solving complex problems takes time and a lot of hard work. It just does. If it were something comparatively simple like flying to the moon, curing CRC would have been done over 40 years ago… But I do firmly believe that after decades of conceptual hope, our cure/long term disease control spaceship is now finally on the launch pad and we have entered the final countdown.  Hopefully the countdown isn’t paused too many times before the clock finally hits zero!  I love the symbolism of this Apollo Saturn rocket photo because it was surrounded by darkness with just a glimmer of hopeful light in a small piece of the sky – as the rocket was lit up with flood lights below in anticipation of a successful launch when its time comes.

Apollo Saturn Rocket on Launch Pad

The December 2nd meeting was only the start of this collaboration of experts.  As I mentioned, the science of immuno-oncology is incredibly complex.  A 1-Day discussion will not answer all the scientific questions but it is a necessary first step for success.  The panel of experts will continue to further discuss the latest scientific information and strategies – with (it bears repeating) a singular goal in mind: to develop a blueprint to better understand the science of immunotherapy in CRC treatment, in order to ultimately maximize its potential to treat ALL forms of CRC


The Currently Incurable Scientist_2

10 Comments on “A Remarkable Colorectal Cancer Immunotherapy Meeting

  1. I too share your concern about the countdown. I am just beginning systemic treatment with folfiri, et.al. I’ve been told the usual time line is two to three years, however I have also been told that advancement in the chemo line come so fast that the survival time for Stage IV moves out. I suspect that statement as I know of no-one who has logically explained how that time line moves and where is it now?

    That said, I follow your blog with expectation and hope and love your attitude. Way to go Tom


    • I’m glad you enjoy the blog Tom – good luck with your own systemic treatment. I know a number of people who have been been stabilized for >5 years but hopefully there will be new options for us to take before then!


  2. Thanks for giving the insider point of view in this blog. Hopeful for the cure in our lifetime and setting the expectation of progress in all areas of CRC.


  3. This is fascinating news and I am hopeful that we’ll have a cure in our lifetimes. Thank you for your commitment to all of us stage IV survivors.


  4. Thank you so much for sharing this information. We were curious as to whether my husband’s oncologist from Johns Hopkins was in attendance but did not see her name. (Nilofer Azad) Joe’s MSI fragment analysis showed 5 of 5 markers were stable. Assuming this puts him in the non-MSI CRC category :(. Love your passion and determination for a cure! Joe has been fighting Stage IV for 6 years!!


    • Thank you for the note Lynn, wishing all the best for you and your husband. Keep up the good fight! Hearing of Joe as well as other 6+ year Stage IV CRC survivors inspires me!

      Liked by 1 person

  5. Pingback: The Faces of Successful Colorectal Cancer Immunotherapies: Vol. 2 | AdventuresInLivingTerminallyOptimistic

  6. Pingback: True Faith (FAVORITE POSTS OF 2016) | AdventuresInLivingTerminallyOptimistic

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s


Scroll naar beneden langs de grote bomen:-)

My Cancered Life

Relentlessly Attacking Cancer Through Fitness, Family, Advocacy, and Laughter


Přejděte dolů kolem velkých stromů :-)


Más allá de los grandes árboles :-)


向下拖动滚动条看看大树底下 :-)


Пролистайте вниз мимо больших деревьев :-)

Cancer Riot

Scroll Down Past the Big Trees :-)

SugarCone Biotech

Research and Development - Analysis, Consulting, Investment

Fightin 4 Blue.org

Colorectal Cancer Awareness

Tami Boehmer | Miracle Survivors

Just another WordPress.com site

Adventures in Spiritual Living

Riding the spiritual waves of everyday life

life and breath: outliving lung cancer

for the terminally optimistic

%d bloggers like this: